Drugs Made In America Acquisition Corp.DMAA

Drugs Made In America Acquisition Corp. (DMAA) has managed to turn the concept of a blank-cheque company into a financial art form. With a $242 million asset base and only $14,887 in actual cash, the company's balance sheet reads like a magic trick. Despite a net income of $2 million and operating losses of $143,301, DMAA has kept its shareholders' equity at a crisp $-7.4 million, showcasing a unique blend of financial ingenuity and regulatory prowess.

DMAA is a Special Purpose Acquisition Company (SPAC) that went public in 2024 with the aim of acquiring a business in the pharmaceutical industry. The company's administrative services agreement, which was cancelled in March 2026, involved paying $10,000 for office space and support services. The $30,000 outstanding at the time of cancellation was converted into a capital contribution, resulting in no outstanding amounts as of March 31, 2026.

DMAA's merger agreement with Power Analytics Global Corp. is a complex document that outlines various conditions for the merger to be completed. These conditions include approval by shareholders, effectiveness of registration statements, and the failure to satisfy those conditions. The company's financials, as reported in its 10-Q filing for the period ending March 31, 2026, show a net income of $2 million, operating losses of $143,301, and a negative shareholders' equity of $-7.4 million.

For those interested in the market mechanism, DMAA's stock is traded on the NASDAQ under the ticker symbol DMAA. The company's financial performance and merger agreement are key factors to watch as they navigate the complexities of the pharmaceutical industry and regulatory environment.